19.1
Astma: Pathogenese en behandeling
Astma is een chronische longaandoening waarbij de luchtwegen ontstoken zijn, er sprake is van hyperreactiviteit en reversibele obstructie van de lucht…
Asthma, a chronic respiratory condition, entails airway inflammation, hyper-reactivity, and reversible obstruction of the airways.
It is categorized as allergic, triggered by allergens like dust, mites, and pet dander, and non-allergic, induced by cold air or intense emotions.
Symptoms of asthma include wheezing, shortness of breath, chest tightness, and sleep disturbances.
The pathogenesis of asthma involves an immune response in genetically predisposed individuals.
It begins with the sensitization phase, where the initial exposure to an allergen prompts the immune system to produce IgE antibodies. These antibodies bind to mast cells in the airway mucosa, priming them.
Re-exposure to allergens triggers the release of inflammatory mediators, causing bronchial contraction, mucus secretion, and vascular leakage.
Hours later, a late-phase response occurs, involving the influx of inflammatory cells and the release of interleukins, which sustains bronchoconstriction, inflammation, and mucus production.
The management of asthma mainly relies on bronchodilators and corticosteroids.
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between allergic and non-allergic asthma?
Allergic asthma is triggered by allergens like dust mites, pollen, and pet dander, involving an IgE-mediated immune response. Non-allergic asthma results from direct airway hyper-responsiveness to non-immune triggers such as cold air, exercise, air pollutants, respiratory infections, or strong emotions. Both types cause similar symptoms including wheezing, shortness of breath, and chest tightness, but through different pathogenic mechanisms.
Q2: How do mast cells contribute to the asthma response?
During sensitization, IgE antibodies bind to mast cells in the airway mucosa, priming them. Upon re-exposure to allergens, primed mast cells release inflammatory mediators like histamine, leukotrienes, and prostaglandins. These substances trigger bronchial muscle contraction, mucus secretion, and vascular leakage, initiating the immediate asthma response. Understanding mast cell activation is central to antiasthma drugs mast cell stabilizers and anti-IgE drugs.
Q3: What happens during the late-phase response in asthma?
Hours after the initial mast cell response, eosinophils and lymphocytes infiltrate the airways and release inflammatory proteins called interleukins. This late-phase response sustains bronchoconstriction, inflammation, and mucus production, contributing to the chronic nature of asthma. The prolonged inflammatory cascade explains why asthma symptoms can persist even after allergen exposure ends.
Q4: How do corticosteroids help manage asthma symptoms?
Corticosteroids such as fluticasone and budesonide are powerful anti-inflammatory agents that reduce swelling and mucus production in the airways. By suppressing the inflammatory response, inhaled corticosteroids and glucocorticoids help prevent bronchoconstriction and restore normal airway function. With appropriate use of these medications, asthmatic individuals can manage symptoms and lead active lives.
Q5: What role do bronchodilators play in asthma treatment?
Bronchodilators such as albuterol and salmeterol act as sympathomimetics that relax bronchial smooth muscles and open the airways. These medications provide rapid relief from bronchoconstriction and restore airflow during asthma attacks. Bronchodilators are essential components of asthma management, often used alongside anti-inflammatory agents for optimal symptom control.
Q6: What inflammatory mediators are released during the asthma response?
Primed mast cells release histamine, leukotrienes, and prostaglandins upon allergen re-exposure. In non-allergic asthma, direct airway activation also releases histamine and leukotrienes. These mediators cause bronchial muscle contraction, mucus secretion, and increased blood vessel permeability, collectively producing the characteristic asthma symptoms of wheezing and airway obstruction.
Q7: How does genetic predisposition influence asthma development?
Asthma pathogenesis involves an immune response specifically in genetically predisposed individuals. During sensitization, these individuals produce IgE antibodies in response to allergen exposure, priming mast cells for future encounters. Genetic factors determine whether the immune system mounts this exaggerated IgE response, making some people susceptible to asthma while others exposed to the same allergens remain unaffected.